Cite
MLA Citation
Lana Zhovtis Ryerson et al.. “071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program.” Journal of neurology, neurosurgery and psychiatry, vol. 89, no. 6, 2018, p. A29. http://access.bl.uk/ark:/81055/vdc_100137792697.0x000035